40,828 Shares in Grifols, S.A. (NASDAQ:GRFS) Purchased by Jane Street Group LLC

Jane Street Group LLC acquired a new position in shares of Grifols, S.A. (NASDAQ:GRFS) in the 3rd quarter, Holdings Channel reports. The fund acquired 40,828 shares of the biotechnology company’s stock, valued at approximately $363,000.

Other large investors have also made changes to their positions in the company. GAMMA Investing LLC raised its holdings in Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 1,135 shares in the last quarter. Signaturefd LLC grew its stake in shares of Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares during the period. AQR Capital Management LLC bought a new stake in shares of Grifols in the 2nd quarter valued at approximately $89,000. HighTower Advisors LLC grew its stake in shares of Grifols by 12.5% in the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 1,546 shares during the period. Finally, Chesapeake Capital Corp IL bought a new stake in shares of Grifols in the 3rd quarter valued at approximately $148,000.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Stock Performance

GRFS stock opened at $7.60 on Thursday. The stock has a 50-day moving average price of $8.11 and a two-hundred day moving average price of $8.16. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $9.96.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.